Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROZAC WEEKLY vs CELEXA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
90 mg orally once weekly
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
Fluoxetine: 4-6 days after single dose, 4-6 days (extended to 7-9 days with chronic dosing due to autoinhibition of CYP2D6); norfluoxetine: 9-31 days. Steady state achieved after 2-4 weeks.
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
Hepatic via CYP2D6, CYP2C9, and CYP3A4; active metabolite norfluoxetine.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Renal excretion of metabolites (primarily fluoxetine glucuronide and norfluoxetine glucuronide) accounts for approximately 80% of elimination; fecal excretion accounts for approximately 15%.
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
Approximately 94.5% bound to plasma proteins, including albumin and alpha-1-acid glycoprotein.
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
12-43 L/kg (average ~25 L/kg). Large Vd indicates extensive tissue distribution, including brain and fat; contributes to prolonged elimination.
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
Oral: ~90% (not significantly affected by food). Weekly formulation: same bioavailability as daily dosing.
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
No dose adjustment required for GFR ≥15 m L/min; insufficient data for GFR <15 m L/min, use with caution.
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
Child-Pugh Class A: no adjustment; Class B: initiate at 20 mg/day (immediate-release) or use alternative; Class C: contraindicated or use with extreme caution.
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
Not approved for use in pediatric patients; safety and efficacy not established.
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
Initiate with 20 mg/day (immediate-release) and increase cautiously; monitor for hyponatremia and SIADH; PROZAC WEEKLY not recommended due to limited data.
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Clinical worsening and suicide risk,Serotonin syndrome,Mania/hypomania,Seizures,Altered platelet function,Angle-closure glaucoma,Hyponatremia,QT prolongation,Sexual dysfunction
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Concomitant use with MAOIs,Concomitant use with pimozide or thioridazine,Known hypersensitivity to fluoxetine
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
Grapefruit and grapefruit juice may increase fluoxetine levels; avoid large amounts. No specific dietary restrictions, but take with food if GI upset occurs.
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
First trimester: Crosses placenta; risk of major congenital malformations based on some studies (e.g., cardiovascular defects approx. 1.8% vs 1% baseline). Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN) approx. 0.3% vs 0.1% baseline. Late trimester: Neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress) in ~30% exposed neonates.
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
Fluoxetine and norfluoxetine are excreted in breast milk. Infant serum concentrations are typically low (<10% maternal weight-adjusted dose). M/P ratio for fluoxetine ~0.8; norfluoxetine ~0.2. Cases of adverse effects (fussiness, poor feeding) are rare. Benefits may outweigh risks in moderate-severe depression.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
No dose adjustment required based on PK studies in pregnancy. However, due to increased volume of distribution and clearance late in pregnancy, some patients may require a dose increase to maintain efficacy; monitor clinical response and adjust dose as needed.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
Fluoxetine has a long half-life (4-6 days; active metabolite norfluoxetine 4-16 days) allowing weekly dosing, but requires daily loading for 13 weeks before switching to weekly. Monitor for serotonin syndrome if co-prescribed with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms despite long half-life.
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
Take once weekly on the same day, typically 90 mg capsule. Do not crush or chew.,May take 4-8 weeks for full therapeutic effect.,Common side effects include nausea, insomnia, drowsiness, sweating, and sexual dysfunction.,Avoid alcohol as it may worsen side effects.,Contact doctor if rash, suicidal thoughts, or serotonin syndrome symptoms occur.,Do not stop abruptly; withdrawal effects possible.
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROZAC WEEKLY vs CELEXA, answered by our medical review team.
PROZAC WEEKLY is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking reuptake of serotonin at the presynaptic neuronal membrane.. CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROZAC WEEKLY and CELEXA depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROZAC WEEKLY is: 90 mg orally once weekly. The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROZAC WEEKLY and CELEXA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROZAC WEEKLY is classified as Category C. First trimester: Crosses placenta; risk of major congenital malformations based on some studies (e.g., cardiovascular defects approx. 1.8% vs 1% baseline). Third trimester: Risk of. CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.